【摘要】 目的探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清高敏C反应蛋白(hs-CRP)和妊娠相关蛋白-A(PAPP-A)水平的影响。方法选择2014年1月至2015年1月我院心内科收治的80例ACS患者,随机将其分为高剂量组与低剂量组,每组40例,分别予阿托伐他汀40 mg/d及20 mg/d治疗,同时选择健康体检者40例及稳定性心绞痛(SAP)患者40例分别纳入对照组及SAP组,比较不同组别研究对象的血清hs-CRP及PAPP-A的水平。结果 ACS组患者的血清hs-CRP与PAPP-A水平均较SAP组与对照组明显升高,差异均有统计学意义(P<0.05);治疗后,高剂量及低剂量组ACS患者血清hs-CRP、PAPP-A水平均较治疗前明显下降,且高剂量组下降比低剂量组更明显,差异均有统计学意义(P<0.05)。结论急性冠脉综合征患者血清hs-CRP与PAPP-A水平明显增高,阿托伐他汀治疗ACS可有效抑制炎症反应,且此效应与剂量有关。更多还原

【Abstract】 Objective To investigate the effect of atorvastatin on serum high-sensitivity C-reactive protein(hs-CRP) and pregnancy associated plasma protein-A(PAPP-A) in patients with acute coronary syndrome(ACS).Methods Eighty patients with ACS(ACS group) treated in Department of Cardiology in our hospital from Jan. 2014 to Jan. 2015 were randomly divided into high-dose group and low-dose group(each group with 40 patients), which were given atorvastatin 40 mg/d and 20 mg/d. Forty healthy people and 40 patients with stable angina pectoris(SAP) were included into the control group and SAP group. The serum hs-CRP and PAPP-A were compared. Results The serum hs-CRP and PAPP-A level in ACS group was significantly increased compared with SAP group and control group(P<0.05). After treatment, the serum hs-CRP, PAPP-A levels in high-dose group and low-dose group were significantly decreased than those before treatment, and the levels in high-dose group were significantly lower than the low-dose group(P<0.05). Conclusion The serum hs-CRP and PAPP-A levels in patients with acute coronary syndrome are significantly increased. Atorvastatin therapy can effectively inhibit the inflammatory response, and this effect is of dose-dependent.更多还原